arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Biomea Fusion, Inc.

BMEA
$1.26 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Biomea Fusion, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $91.1M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -53.9%
FCF / Share $-0.16
Trailing P/E
Price / Book 4.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$165.00M
↓ -84.6%
Net Income Profit after all expenses
$-12.41M
↑ +57.6%
Operating Margin Operating profit as % of sales
-14.2%
↓ -828.6%
FCF / Share Free cash flow per share
$-0.16
↑ +77.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Cash Quality
71

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters